key: cord-0804689-hvg70056 authors: Khan, Tariq; Jamal, Syed Muhammad title: SARS-CoV-2 nomenclature: viruses, variants and vaccines need a standardized naming system date: 2021-11-04 journal: Future virology DOI: 10.2217/fvl-2021-0198 sha: 55479e659747e5548994e8dfe9f4013264cf9c9f doc_id: 804689 cord_uid: hvg70056 nan The International Committee on Taxonomy of Viruses (ICTV) has now approved and ratified a binomial genusspecies naming system for virus species. This approval came in March 2021 after the meeting of ICTV Executive Committee in October 2020 [5] . The ICTV has suggested that all previously established species names be converted to the new format. However, as of now, no proper implementation measures have been stated. Researchers, the media, and government officials continue to call the virus names that ignore the new ICTV rules. This is due in part to the complexity of the binomial nomenclature. While bringing binomial nomenclature to viral taxonomy is a positive step, these names are very difficult for the public. For everyday use, short and catchy names like Measles are highly recommended. The WHO should urge governments, the media, and other public entities to continue to refer to the virus such as 'the coronavirus', while avoiding any other derogatory terms. The scientific community should, however, adopt the new nomenclature as soon as possible. When it is suggested that political correctness is important while naming deadly viruses, it is because some entities are happy to call them by names that stigmatize those places and people. A recent example is that of the new variant 'B.1.617.2' dubbed 'Indian variant' as reported in a New Scientist Magazine article [6] . Similarly, the previous variants B.1.1.7, B.1.351 and P.1 are referred to as the UK, South Africa and Brazil variants, respectively [3] . Such nomenclature results in racism and xenophobia. For example, calling the variant with names such as 'Indian variant' has sparked a wave of prejudice against Indians. To avoid these issues, the four coronavirus variants that the WHO considers as variants of concern, have now been assigned the Greek letters Alpha, Beta, Gamma and Delta, in order of their detection [7] . Other proposals, such as naming the variants after Greek gods, fruits, plants or acronyms for the phrase 'variant of concern' (VOC1, VOC2), were discussed but rejected by the panelists for a variety of reasons. According to the WHO, the new names (Alpha, Beta, Gamma and Delta) are intended to be simple and avoid prejudice, and they will not replace existing scientific names (such as B.1.1.7, B.1.351 and P.1 assigned by Pangolin [8] , which convey important scientific information. This is a good first step. However, there is an issue with assigning variants the Greek letters. In attempting to avoid one problem, the WHO has ended up causing another. As stated earlier, SARS-CoV-2 belongs to the genus Betacoronaviruses. The names of the variants of SARS-CoV-2, in other words, Alpha, Beta, Gamma and Delta have created another confusion with the names of the genera (Supplementary Figure 1) . While deciding on these names, the confusion with assigning variants names that already correspond to the coronavirus genera should have been considered. As the goal was to achieve ease of use and simplicity, naming the variants in a much simpler and straightforward manner, such as variant A (Var-A), variant B (Var-B), variant C (Var-C), and so on, could have been a better option. Just like naming SARS-CoV-2 and its variants, there has also been some confusion about the names of the vaccines. Currently, 21 COVID vaccines have been approved for use in at least one country (Supplementary Table 1 ). The WHO has given emergency use authorization to six of these vaccines [9] . Name of the manufacturer, the method of development, and the country of development are all used interchangeably to identify these vaccines. This has created confusion. For example, people confuse the terms "SinoVac" and "CoronaVac" vaccines, when CoronaVac is a vaccine manufactured by SinoVac Biotech Ltd., a Chinese biopharmaceutical company. Furthermore, Sinopharm, a biopharmaceutical company, has developed BBIBP-CorV and WIBP-CorV, two traditionally inactivated vaccines. Both the vaccines have been approved for emergency use. BBIBP-CorV has been dubbed more effective than WIBP-CorV [10] . It has also been approved by the WHO. However, both vaccines are referred to as Sinopharm, with no distinction made between them. Similarly, the Ad26.COV2.S vaccine was developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, a multinational corporation. This vaccine is also named, interchangeably, as the Janssen or Johnson & Johnson vaccine [11, 12] , which ultimately causes confusion among the general public. Vaccine refusal is as old as the vaccines themselves. It takes an inordinate amount of effort, resources, and time to persuade people to get vaccinated [13] . Just as health authorities, governments, and the media are responsible for promoting vaccination, they are also responsible for naming the vaccines in a consistent manner to avoid confusion. In conclusion, an effective system of nomenclature should be in place to standardize names of viruses, variants, and vaccines as quickly as possible. The ICTV should act swiftly to bring these names forward. To avoid prejudice, 10 .2217/fvl-2021-0198 Future Virol. (Epub ahead of print) future science group SARS-CoV-2 nomenclature: viruses, variants & vaccines need a standardized naming system Editorial misconceptions and stigmatization related to such nomenclatures, governments, public entities, and the media should act responsibly in accordance with the conventions. Because of the world's deadliest outbreak caused by SARS-CoV-2, virus nomenclature is expected to take a serious turn. Furthermore, it is expected that more than 100,000 complete SARS-CoV-2 genome sequences will be generated in near future. It is also expected that more variants will emerge soon, necessitating a very clearly laid out nomenclature system to avoid confusion. In addition to variants, new viruses, more lethal than the current one, may emerge and quickly spread around the world. Failure to prepare in every aspect of virus biology may allow the next epidemic to be far more devastating than the current one. Naming viruses and variants according to their geographical location of first detection or nationality in which they were first observed, and given the fact that the developed world is rapidly recovering, there is a risk of stigmatization growing in relation to variants emerging in developing countries. It is expected that significant efforts will be made to establish an easy-to-use standard nomenclature system for viruses. To view the supplementary data that accompany this papers please visit the journal website at: www.futuremedicine.com/doi/sup pl/10.2217/fvl-2021-0198 Financial & competing interests disclosure Virus taxonomy: one step forward, two steps back Encyclopedia of Virology WHO. Tracking SARS-CoV-2 variants The tricky politics of naming the new coronavirus Changes to virus taxonomy and to the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2021) New Scientist. Indian covid-19 variant WHO announces simple, easy-to-say labels for SARS-CoV-2 variants of interest and concern A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology Covid19 Vaccine Tracker. 7 vaccines approved for use by WHO Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial Johnson coronavirus vaccine's benefits still outweigh risks, CDC data show Johnson vaccine far less effective against delta variant, study suggests The anti-vaccination movement: a regression in modern medicine The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.